Apr 29, 2026
EyeCool Therapeutics Announces New ETX-4143 Data to Be Presented at ARVO 2026
Jan 15, 2026
Ruben F. Salinas and Greg Kunst on the hidden epidemic of chronic ocular pain
Jan 08, 2026
EyeCool Therapeutics Announces Encouraging Interim Clinical Results for ETX-4143 in Chronic Ocular Surface Pain
Sept 02, 2025
EyeCool Therapeutics Appoints Dr. Vance Thompson to Board of Directors
May 07, 2025
EyeCool Therapeutics Announces Promising Results from Double-Masked Randomized Controlled Trial in Chronic Ocular Surface Pain (COSP)
